Dana Farengo Clark, MS, LCGC, Penn Medicine
Articles by Dana Farengo Clark, MS, LCGC, Penn Medicine

Operational Processes and Challenges
ByMark E. Robson, MD, Memorial Sloan Kettering Cancer Center,John Henson, MD, Augusta University,Ashley Ross, MD, PhD, Northwestern Medicine,Dana Farengo Clark, MS, LCGC, Penn Medicine Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.

Role of ctDNA in Germline Testing
ByMark E. Robson, MD, Memorial Sloan Kettering Cancer Center,John Henson, MD, Augusta University,Ashley Ross, MD, PhD, Northwestern Medicine,Dana Farengo Clark, MS, LCGC, Penn Medicine Mark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss the evolving role of circulating tumor DNA (ctDNA) in germline testing.

Identification of Patients for Germline Testing
ByMark E. Robson, MD, Memorial Sloan Kettering Cancer Center,John Henson, MD, Augusta University,Ashley Ross, MD, PhD, Northwestern Medicine,Dana Farengo Clark, MS, LCGC, Penn Medicine The panel of experts provide insight on how they identify patients for germline testing.

Experience with Interpreting Somatic Reports
ByMark E. Robson, MD, Memorial Sloan Kettering Cancer Center,John Henson, MD, Augusta University,Ashley Ross, MD, PhD, Northwestern Medicine,Dana Farengo Clark, MS, LCGC, Penn Medicine A panel of experts share their experiences with interpreting information on somatic reports and provide recommendations for verifying results.

Tumor-Normal Matched Sequencing and Platforms Utilized for Tumor Profiling
ByMark E. Robson, MD, Memorial Sloan Kettering Cancer Center,John Henson, MD, Augusta University,Ashley Ross, MD, PhD, Northwestern Medicine,Dana Farengo Clark, MS, LCGC, Penn Medicine Mark Robson, MD, reviews data from a recent abstract on incidental germline findings detected by tumor-normal matched sequencing and the panelists share which platforms they utilize for tumor profiling.

Defining Germline Sequencing and Incidental Germline Findings
ByMark E. Robson, MD, Memorial Sloan Kettering Cancer Center,John Henson, MD, Augusta University,Ashley Ross, MD, PhD, Northwestern Medicine,Dana Farengo Clark, MS, LCGC, Penn Medicine Mark Robson, MD, and a panel of experts discuss key terminology and definitions related to tumor and germline sequencing.